Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) is a company based in New York, United States. It is an alliance between Ichnos Sciences Inc., a global clinical-stage biotechnology company, and Glenmark Pharmaceuticals Ltd. IGI employs 144 people and generates $50 million in annual revenue. IGI focuses on developing curative therapies for cancer, aiming to extend and improve the lives of patients. Their expertise lies in researching and developing novel biologics and small molecules, targeting hematological malignancies and solid tumors. IGI distinguishes itself through its collaborative approach, combining the strengths of Ichnos Sciences' research and development capabilities in biologics with Glenmark Pharmaceuticals' expertise in small molecules. This alliance leverages the expertise of over 150 scientists across three global innovation centers in the USA, Switzerland, and India. Visit IGI's website at iginnovate.com for more information.